Search Results

• • 25 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• A Python-based programming language for high-performance computational genomics.

  Authors:Ariya Shajii, Ibrahim Numanagic, Alexander T. Leighton, Haley Greenyer, Saman Amarasinghe, and Bonnie BergerFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20211,454 words Article 1820LAuthor(s): Ariya Shajii 1 , Ibrahim Numanagic 1 2 , Alexander T. Leighton 1 3 , Haley Greenyer 2 , Saman Amarasinghe 1 , Bonnie Berger 1 3 Author Affiliations: (1) Computer Science and Artificial Intelligence...

• More than just content: building community in the graduate classroom.

  Authors:Madhvi J. Venkatesh, Alexandra R. Elchert, Bolutife Fakoya, Francisco Fernandez, Andrew C. Kwong, Yue J. Liu, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20214,141 words Article 1470LCommunity building should be integrated into the graduate classroom to foster the development of a professional identity and build connections between students and faculty. Author(s): Madhvi J. Venkatesh 1 13 ,...

• Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.

  Authors:Wenming Xiao, Luyao Ren, Zhong Chen, Li Tai Fang, Yongmei Zhao, Justin Lack, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 202112,630 words Article 1450LClinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing...

• Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease.

  Authors:Ro'ee Gilron, Simon Little, Randy Perrone, Robert Wilt, Coralie de Hemptinne, Maria S. Yaroshinsky, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 202111,158 words Article 1570LNeural recordings using invasive devices in humans can elucidate the circuits underlying brain disorders, but have so far been limited to short recordings from externalized brain leads in a hospital setting or from...

• Responsible governance of gene editing in agriculture and the environment.

  Authors:Doria R. Gordon, Gregory Jaffe, Michael Doane, Aviva Glaser, Thomas M. Gremillion, and Melissa D. HoFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20212,757 words Article 1450LAuthor(s): Doria R. Gordon 1 , Gregory Jaffe 2 , Michael Doane 3 , Aviva Glaser 4 , Thomas M. Gremillion 5 , Melissa D. Ho 6 Author Affiliations: (1) Environmental Defense Fund, Washington, USA (2) Center for...

• Sequencing benchmarked.

  From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 2021989 words Article 1570LThe Sequencing Quality Control 2 (SEQC2/MAQC-IV) project provides resources to aid sequencing reproducibility and highlights factors that can guide platform and software choice. Author Affiliations: SEQC2 is the most...

• Oncologists greet Lumakras: the world's first KRAS inhibitor.

  Author:Cormac SheridanFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20212,183 words Article 1480LThe milestone approval for Amgen's drug Lumakras will galvanize targeted therapy efforts against Ras oncoproteins and provides a powerful new last line of defense for patients with lung cancer. Author(s): Cormac...

• First interchangeable insulin.

  From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 2021263 words Brief article Author Affiliations: The US Food and Drug Administration has approved the first interchangeable biosimilar insulin, a move that promises better access and lower cost to people with types 1 and 2 diabetes. Semglee...

• Performance assessment of DNA sequencing platforms in the ABRF Next-Generation Sequencing Study.

  Authors:Jonathan Foox, Scott W. Tighe, Charles M. Nicolet, Justin M. Zook, Marta Byrska-Bishop, Wayne E. Clarke, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 202110,951 words Article 1520LAssessing the reproducibility, accuracy and utility of massively parallel DNA sequencing platforms remains an ongoing challenge. Here the Association of Biomolecular Resource Facilities (ABRF) Next-Generation Sequencing...

• The lag in SARS-CoV-2 genome submissions to GISAID.

  Authors:Kishan Kalia, Gayatri Saberwal, and Gaurav SharmaFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20211,892 words Article 1490LAuthor(s): Kishan Kalia 1 , Gayatri Saberwal 1 , Gaurav Sharma 1 Author Affiliations: (1) Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru, India To the Editor -- Genomic surveillance of the...

• Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.

  Authors:Ira W. Deveson, Binsheng Gong, Kevin Lai, Jennifer S. LoCoco, Todd A. Richmond, Jeoffrey Schageman, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 202112,739 words Report 1620LCirculating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of a...

• People.

  From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 2021807 words Article 1350LRecent moves of note in and around the biotech and pharma industries. Author Affiliations: Landmark Bio has announced the appointment of Ran Zheng (photo) as CEO. Zheng is an industry veteran with more than 25 years...

• First HIF-2 antagonist for VHL tumors.

  From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 2021237 words Brief article 1350LAuthor Affiliations: The US Food and Drug Administration has approved Welireg (belzutifan), an oral HIF-2[alpha] inhibitor, for treating adults with cancers linked to the rare genetic disorder von Hippel-Lindau (VHL)...

• MAQC and the era of genomic medicine.

  Authors:Marc Salit and Janet WoodcockFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20211,480 words Article 1550LThe MicroArray Quality Control consortium--a 16-year international effort led by the FDA and involving hundreds of scientists from academia, industry and government--helped make genomic medicine a reality. Author(s):...

• Startups set off new wave of mRNA therapeutics.

  Author:Elie DolginFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20212,375 words Article 1500LAfter the vaccine triumphs of Pfizer/BioNTech and Moderna, a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics. Author(s): Elie Dolgin 1 Author Affiliations: (1) Somerville, USA...

• The need for new test verification and regulatory support for innovative diagnostics.

  Authors:John D. Roback, Erika A. Tyburski, David Alter, Saja Asakrah, Ann Chahroudi, Annette Esper, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20212,235 words Article 1780LAuthor(s): John D. Roback 1 , Erika A. Tyburski 7 10 , David Alter 1 , Saja Asakrah 1 , Ann Chahroudi 3 4 , Annette Esper 5 , Sarah Farmer 2 , Janet Figueroa 3 , Jennifer K. Frediani 6 , Mark D. Gonzalez 4 , David S....

• Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.

  Authors:Li Tai Fang, Bin Zhu, Yongmei Zhao, Wanqiu Chen, Zhaowei Yang, Liz Kerrigan, et al.From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 202114,043 words Report 1450LThe lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics. Here, we...

• Nature Biotechnology's academic spinouts 2020.

  Authors:Michael Eisenstein, Ken Garber, Esther Landhuis, Caroline Seydel, and Laura DeFrancescoFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 202111,853 words Article 1360LNature Biotechnology's annual survey highlights university startups that are, among other things, rethinking how to deliver gene-editing therapy and tackling various metabolic conditions, immune disorders and cancer with...

• Stepping to the exit.

  Authors:Christiaan M. de Bloeme, Robin W. Jansen, Mark R. L. Krul, and Ernst-Jan GeutjesFrom:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 20215,497 words Article 1440LA historical analysis of oncology deals can help bioentrepreneurs navigate the right time for partnerships and exits and can inform on the type of investors likely to be interested. Author(s): Christiaan M. de Bloeme 1...

• Organoids.

  From:Nature Biotechnology (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 2021401 words Table Recent patents relating to methods of making and using organoids. Author Affiliations: US 11,053,477 Methods of inducing formation of gastric cells and/or gastric tissues, such as in the form of a gastric organoid....